Fig. 4. Cumulative incidence of locoregional progression or recurrence (LRPR), with competing risk of death, among patients with de novo HER2-positive metastatic inflammatory breast cancer (mIBC) who were alive and free of LRPR at 12 months since diagnosis, according to receipt of surgery.

Among patients diagnosed with de novo HER2-positive mIBC alive and free of LRPR at 12 months from diagnosis (n = 56), 10 patients subsequently developed LRPR. The cumulative incidence of LRPR over the subsequent 1 and 2 years from the 12-month landmark was 10.8% (95% CI: 4.3–20.6) and 14.8% (95% CI: 6.9–25.7), respectively. Cumulative incidence of LRPR is shown as the blue line; competing risk of death is shown as the dashed black line. CI confidence interval; HER2 human epidermal growth factor receptor 2; yr year.